Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain
A Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open-label Run-in to Assess the Efficacy and Safety of Hydrocodone Bitartrate (HYD) Tablets 20 to 120 mg Once-daily in Subjects With Moderate to Severe Chronic Low Back Pain
Sponsor: Purdue Pharma LP
A PHASE3 clinical study on Chronic Low Back Pain, this trial is completed. The trial is conducted by Purdue Pharma LP and has accumulated 10 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jul 2018 — Apr 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Nov 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Purdue Pharma LP
For direct contact, visit the study record on ClinicalTrials.gov .